Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Keta-Care - Antidepressant and Anxiolytic Effects of Intranasal Ketamine Self-administration in Palliative Care Cancer Patients: an Open-label Feasibility Study

NCT06665568 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT06665568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06665568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Keta-Care - Antidepressant and Anxiolytic Effects of Intranasal Ketamine Self-administration in Palliative Care Cancer Patients: an Open-label Feasibility Study
Lead sponsor
University of Zurich
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2025
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, caregiver burden, depressive symptoms mild to moderate in severity, quality of life (qol), sleep quality